Biofrontera Inc. price target lowered to $2.75 from $7 at Benchmark

Benchmark analyst Bruce Jackson lowered the firm’s price target on Biofrontera Inc. (BFRI) to $2.75 from $7 and keeps a Buy rating on the shares. After Q1 revenue of $8.6M lagged the firm’s $10.6M estimate, its new revenue estimate is $41.1M for 2025, down from $43.1M, notes the analyst, who adds that historic sales patterns would suggest that the “already seasonally heavy” Q4 will be “the key to this year’s revenue growth.”